MENLO PARK, Calif.--(BUSINESS WIRE)--iScience Interventional (iScience, Menlo Park, CA), pioneers of site-specific therapies for anterior and posterior ocular diseases, today announced it has signed a clinical and commercial supply agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) and its affiliates. In this agreement, iScience will supply iTrack 275 microcatheters for the delivery of J&JPRD’s cell therapy, CNTO2476, which is currently in clinical trials for the treatment of retinal degeneration.
